TRVI — Trevi Therapeutics, Inc. stock price, charts and financials

QT79Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
14.95
-0.26-1.71%
OverviewShort InterestFilings
TRVIQT79Trevi Therapeutics, Inc.·NASDAQ
14.95-1.71%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
SRPT-2.71%$20.11ADMA+1.79%$9.11SLS-0.35%$11.49URGN-1.59%$43.25PVLA-2.44%$150.56AUPH-0.35%$16.90OCUL-1.48%$9.99BHVN-1.94%$13.62
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand141.98MPerf Week-5.97%
Market Cap2.12BForward P/E-EPS next Y-0.61Insider Trans-0.01%Shs Float118.77MPerf Month-20.52%
Enterprise Value1.93BPEG-EPS next Q-0.13Inst Own-Short Float10.11%Perf Quarter-13.13%
Income-43.00MP/S0.00EPS this Y-Inst Trans-Short Ratio5.62Perf Half Y39.72%
Sales0.00P/B11.17EPS next Y-27.80%ROA-15.46%Short Interest12.01MPerf YTD19.41%
Book/sh1.34P/C10.89EPS next 5Y-ROE-23.59%52W High20.22 -26.06%Perf Year87.34%
Cash/sh1.37P/FCF-EPS past 3/5Y-ROIC-18.46%52W Low8.03 86.18%Perf 3Y592.13%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility4.00% 4.14%Perf 5Y883.55%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM27.66%Oper. Margin0.00%ATR (14)0.74Perf 10Y-
Dividend Ex-Date-Quick Ratio37.28Sales Y/Y TTM-Profit Margin0.00%RSI (14)28.46Recom1.94
Dividend Gr. 3/5Y-Current Ratio37.28EPS Q/Q-22.22%SMA20-10.09%Beta0.91Target Price29.67
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-14.51%Rel Volume0.99Prev Close15.21
Employees34LT Debt/Eq0.01EarningsNov 12SMA2005.26%Avg Volume2.15MPrice14.95
IPO DateMay 07, 2019Option/ShortYes / YesEPS/Sales Surpr.-0.49% -Net Debt/EBITDA1.05Volume2,138,487Change-1.71%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedMorgan StanleyOverweight$20 → $23
Aug-07-26ReiteratedRaymond JamesStrong Buy$40
Aug-07-26ReiteratedOppenheimerOutperform$24 → $25
Jul-20-26ReiteratedHC Wainwright & Co.Buy$6.00 → $24
May-08-26ReiteratedStifel NicolausBuy$18 → $30
May-06-26ReiteratedMorgan StanleyOverweight$18 → $20
Dec-19-25ReiteratedStifel NicolausBuy$15 → $18
Nov-14-25ReiteratedOppenheimerOutperform$12 → $24
Nov-14-25ReiteratedMorgan StanleyOverweight$19
Mar-10-25UpgradeRaymond JamesOutperform → Strong Buy
Latest News· Times ET
Sep-15-26
Sep-15-2607:41PM
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com
Sep-05-26
Sep-05-2601:05PM
Trevi Therapeutics (TRVI) Stock Trades At A Premium To Fair ValueYahoo
Sep-03-26
Sep-03-2603:30AM
Trevi Therapeutics to Participate in Upcoming September Conferencesglobenewswire.com
Aug-26-26
Aug-26-2603:30AM
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026globenewswire.com
Aug-19-26
Aug-19-2609:19PM
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platformseekingalpha.com
Aug-14-26
Aug-14-2604:52AM
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28Benzinga
Aug-07-26
Aug-07-2610:05AM
Trevi Therapeutics Q2 Earnings Call Highlightsmarketbeat.com
07:21AM
Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $25Benzinga
Aug-06-26
Aug-06-2603:44PM
Trevi Therapeutics, Inc. (TRVI) Q2 2026 Earnings Call Transcriptseekingalpha.com
12:11PM
Trevi Therapeutics Q2 EPS $(0.11), InlineBenzinga
12:05PM
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.com
Jul-30-26
Jul-30-2612:05PM
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026globenewswire.com
Jul-28-26
Jul-28-2603:30AM
Trevi Therapeutics to Participate in Upcoming August Conferencesglobenewswire.com
Jul-21-26
Jul-21-2607:14AM
This Fortinet Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For TuesdayBenzinga
Jul-14-26
Jul-14-2604:05AM
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga
Company

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
000——————
Selling, General and Administrative Excl. Other161210——————
Research and Development333924——————
Other Operating Expense010——————
Operating Income-49-52-34——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)745——————
Net Income Before Taxes-43-48-29——————
Income Taxes
000——————
Consolidated Net Income-43-48-29——————
Net Income From Continuing Operations-43-48-29——————
Net Income-43-48-29——————
EPS (Recurring)-0.29-0.47-0.29——————
EPS (Basic, Before Extraordinaries)-0.29-0.47-0.29——————
EPS (Diluted)-0.29-0.47-0.29——————
EBITDA-43-48-29——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding14510199——————
Market Capitalization1,815416133——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$21.44$17.23$13.02$8.82$4.61● Close Price0.00K79.44K158.88K238.32K317.75KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Heffernan Michael ThomasDirectorSep 15 '26Option Exercise3.1939,473126,10327,403Sep 17
Heffernan Michael ThomasDirectorSep 15 '26Sale15.0921,052317,7546,351Sep 17
Walker Paul Edward10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
Florence Anthony A. Jr.10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
SANDELL SCOTT D10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
Behbahani Ali10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
BASKETT FOREST10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
Makhzoumi Mohamad10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
New Enterprise Associates 16, L.P.10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
Chang Carmen10% OwnerApr 17 '25Option Exercise1.371,851,8522,537,0370Feb 13
Galletta ChristopherSee RemarksDec 02 '25Option Exercise0.514,2252,15926,095Dec 03
SCIASCIA THOMASChief Scientific OfficerMar 25 '25Option Exercise1.432,6313,762224,004Mar 26
SCIASCIA THOMASChief Scientific OfficerMar 25 '25Sale6.602,63117,365221,373Mar 26
GOOD JENNIFER LPresident & CEOMar 21 '25Option Exercise1.435,2637,526218,576Mar 25
GOOD JENNIFER LPresident & CEOMar 21 '25Sale6.585,26334,625213,313Mar 25
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.